WeVote
Log In

Bill

Bill

HB 2536

Relating to step therapy for metastatic cancer treatment.

2025 Regular Session Introduced by Lew Frederick and 3 co-sponsors

HB 2536 prohibits step therapy requirements for metastatic cancer patients, allowing faster insurance approval of oncologist-prescribed treatments instead of mandatory cheaper alternatives first.

In committee upon adjournment.
0
WeVote Research Nonpartisan
Bill Summary · HB 2536

Legislative bill overview

HB 2536 restricts "step therapy" protocols for metastatic cancer patients, requiring insurance companies to allow faster access to prescribed cancer treatments rather than requiring patients to first try cheaper alternative drugs. The bill aims to prevent delays in treatment for advanced cancer cases where time is medically critical.

Why is this important

Metastatic cancer (cancer that has spread) is life-threatening, and treatment delays can meaningfully impact survival outcomes. Step therapy, while cost-controlling for insurers, can postpone access to potentially more effective medications by mandating patients exhaust other options first—a process that may take weeks or months.

Potential points of contention

  • Cost implications: Removing step therapy requirements could increase insurance premiums and healthcare costs by bypassing cheaper first-line treatments
  • Medical evidence standards: Disagreement over whether oncologists' treatment recommendations should automatically override insurer review processes for metastatic cases
  • Scope definition: Unclear whether "metastatic cancer" applies to all cancer types or specific ones, and how broadly exemptions from step therapy would apply

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.